Molecular assay provider Seegene USA has collaborated with Microbix Biosystems for the latter’s QAPS.
Under the deal, Seegene will supply and recommend the QAPs for monitoring the workflow accuracy of Seegene Novaplex and Allplex assays used across the US.
Microbix QAPs are ready for use in polymerase chain reaction (PCR) based (molecular) assays designed for Copan FLOQSwabs in both room-temperature stable formats and liquid vials that remain stable at refrigerator temperatures.
Microbix PROCEEDx QAPs are designated as research use only (RUO) samples, whereas its REDx QAPs are classified as in-vitro diagnostic (IVD) controls.
Microbix business development SVP Phillip Caselli said: “Our longstanding relationship with Seegene Canada laid a strong foundation for this Microbix – Seegene USA relationship.
“Our collaboration naturally aligns the two companies to help assure optimal results for laboratories performing high-multiplex PCR testing using Seegene Assays.”
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
With this agreement, Seegene USA will now provide Microbix’s QAPs in addition to its existing range of high multiplex PCR assays.
These assays detect infectious disease pathogens and fall under Seegene’s Allplex and Novaplex brands.
Utilising Seegene’s technology, the assays have a distinctive capability to yield comprehensive results using just one channel in a PCR reaction.
Seegene USA marketing SVP Craig Howell said: “In this partnership, we are again increasing our IVD presence for the US and further supporting our lab customers in their mission to better provide quality results for their patients and institutions.
“As well, we believe our ongoing IVD assay development requires custom control and validation panel expertise that is met by Microbix’s competencies.”
In September 2023, Seegene and Springer Nature announced the ‘Open Innovation Program powered by Seegene’ (Open Innovation Program) for the development of syndromic quantitative PCR (qPCR) assays.
Available across the globe, the programme will allow scientists, clinicians and experts to develop the assays across all fields.
